CDR-Life to Present at the American Society of Hematology’s 2021 Annual Meeting

November 8, 2021 5:21 pm Published by

Zürich, Switzerland, November 8, 2021CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics based on its proprietary antibody-based T cell engager technology, today announced that preclinical data from the Company’s CDR101 candidate will be  presented  in a poster at the 63rd Annual American Society of Hematology (ASH) meeting being held in Atlanta, Georgia from December 11 -14, 2021.

Details for the poster presentation are as follows:

Abstract Number: 1583

Poster Title: Preclinical Assessment of CDR101 – a BCMAxCD3xPD-L1 Trispecific Antibody with Superior Anti-Tumor Efficacy

Session Number & Name: 651.Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I Hematology Disease Topics & Pathways: Biological, Translational Research, Bispecific Antibody Therapy, Plasma Cell Disorders, Checkpoint Inhibitor, Diseases, Therapies, Lymphoid Malignancies

Session Date: Saturday, December 11, 2021

Session Time: 5:30 PM – 7:30 PM

Presenter: Melissa Vrohlings, Immunology Expert, CDR-Life

Categorised in:

This post was written by CDR Life Editor